Kintor Pharmaceutical Limited
KNTPF
$0.3643
$0.034910.60%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | 347.50K | 349.20K | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 347.50K | 349.20K | -- | -- | -- |
| Cost of Revenue | 295.30K | 296.80K | -77.90K | -78.60K | -285.70K |
| Gross Profit | 52.20K | 52.50K | 77.90K | 78.60K | 285.70K |
| SG&A Expenses | 3.75M | 3.77M | 2.46M | 2.48M | 2.51M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -1.21M | -1.21M | -179.80K | -181.40K | 36.20K |
| Total Operating Expenses | 5.53M | 5.56M | 4.92M | 4.96M | 55.88M |
| Operating Income | -5.19M | -5.21M | -4.92M | -4.96M | -55.88M |
| Income Before Tax | -5.82M | -5.85M | -4.94M | -4.98M | -59.29M |
| Income Tax Expenses | 0.00 | 0.00 | 1.20K | 1.30K | -521.70K |
| Earnings from Continuing Operations | -5.82M | -5.85M | -4.94M | -4.98M | -58.77M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -5.82M | -5.85M | -4.94M | -4.98M | -58.77M |
| EBIT | -5.19M | -5.21M | -4.92M | -4.96M | -55.88M |
| EBITDA | -4.70M | -4.73M | -4.49M | -4.53M | -55.41M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.01 | -0.14 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.08 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.01 | -0.14 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.08 |
| Average Basic Shares Outstanding | 431.02M | 431.02M | 430.43M | 430.43M | 429.69M |
| Average Diluted Shares Outstanding | 431.02M | 431.02M | 430.43M | 430.43M | 429.69M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |